Kornimate/medical-research-clean huggingface dataset:
impact of computerized reminders on blood pressure documentation and control

Conditions: Hypertension

Summary: numerous studies have examined potential causes for the racial differences in htn prevalence and severity including baseline insulin levels, sympathetic nervous activity, intracellular calcium levels and intracellular sodium levels.\[21-23\] however, to our knowledge, there have been no studies examining the relationship of physician adherence to jnc guidelines to racial disparities in outcomes from htn; nor have there been published studies examining the use of interventions such as computerized decision support tools or case-management to improve jnc adherence with the goal of reducing racial differences in blood pressure control. the aims of this study are: 1) to determine if physician's prescribing practices for htn medications adhere to jnc guidelines for drug therapy. 2) to determine if there are variations in adherence to jnc guidelines based on patient race. 3) to determine if adherence to jnc guidelines improves blood pressure control. 4) to determine if the use of computerized medical reminders improves adherence to jnc guidelines.


Eligibility criteria:
inclusion criteria: we examined data obtained from the electronic medical record review of patients older than 20 years with a diagnosis of hypertension, with at least one hypertension-related outpatient visit to one of fourteen general medicine clinics in community health centers, community-based practices, and hospital-based practices affiliated with a large urban academic medical center during the one-year period prior to the beginning of the intervention trial. exclusion criteria: patients without documented hypertension-related primary care visits or less than 20 years of age
premaprob. probiotics to prevent necrotizing enterocolitis

Conditions: Premature Infants; Necrotizing Enterocolitis

Summary: the main objective of this study is to assess the impact of two different doses of a mixture of probiotics from two strains isolated in human milk on the incidence of severe necrotizing enterocolitis (nec) and death among preterm infants of gestational age less than or equal to 32 weeks of gestation and weighing between 750 and 1500 g.


Eligibility criteria:
inclusion criteria: * preterm infants of gestational age less than 33 weeks of gestation with birth weight below 1500 g, admitted to the neonatology unit. * premature newborns who meet the above criteria and receive enteral feeding (mother breast milk, donors milk and/or premature formula) from the amount of 5 ml/kg/day. exclusion criteria: * any clinical circumstance that prevents the initiation of enteral nutrition in the first 72 hours of life. * chromosomopathies and complex fetal malformations, incompatible with enteral nutrition in the first 72 hours of life. * non-acceptance of informed consent to participate in the study by the parents or legal guardians of the newborn.
phenodm1 (myotonic dystrophy type 1 natural history study)

Conditions: Myotonic Dystrophy Type 1

Summary: phenodm1 will use patient reported outcomes to assess levels of pain, fatigue and quality of life in this cohort. clinical and functional outcomes will look at muscle wasting and levels of myotonia. dna, rna, serum and csf samples will be taken from all patients so that additional genetic and molecular biomarker analysis can be carried out. a subset of patients will undergo detailed sleep studies along with skeletal muscle mri of the lower limbs. this study will complement the work of other groups currently looking at myotonic dystrophy type 1 using the same outcomes and measures where possible.

myotonic dystrophy type i (dm1) is the most common form of adult muscular dystrophy, affecting 1 in 8000 individuals. it is an autosomal dominant disorder with multisystemic involvement of multiple organs and tissues, namely brain, heart, endocrine system, eyes and both smooth and skeletal muscles. it results from the ctg expansion of an untranslated region 3' terminal of the dmpk gene which causes a disturbance of the rna metabolism, in particular defective splicing of various pre-mrnas such as the muscular chloride channel (causing myotonia), the insulin receptor (causing diabetes) and others. we will carry out an in-depth characterisation of 400 adult dm1 patients identified from local clinical populations across england and through the national dm registry. over a two year period we will take measurements 12 months apart to address specific symptoms that cause major quality of life impairment including muscle weakness, myotonia, excessive daytime sleepiness and cognitive impairment. dna samples will be collected in order to determine the ctg repeat length and serum samples for biomarker identification. we will carry out muscle mri and sleep studies in a subset of 50 patients. the implemented measures will capitalise on the efforts of previous cohort studies ensuring that all measures are comparable with existing datasets.

Eligibility criteria:
inclusion criteria: main inclusion criteria 1. 18 years of age or over 2. genetic confirmation of myotonic dystrophy type 1 3. able to consent and willing to participate throughout the duration of the study. additional inclusion criteria for mri study: 1. aged between 18 and 55 years 2. ambulant or ambulant-assisted additional inclusion criteria for sleep study: 1. aged between 18 and 55 years exclusion criteria: main exclusion criteria 1. inability to give informed consent 2. if the clinician presumes that the patient will not be able to perform any of the motor function tests involved (six minute walk test, 30 seconds sit and stand test, timed 10-meter walk test) 3. inability to perform the cardiac and pulmonary assessments additional exclusion criteria for mri study: 1. pacemaker, icd or non-mri-compatible prosthetic material. additional exclusion criteria for sleep study: 1. ventilated patients 2. patients medicated with stimulants, including modafinil 3. patients medicated with benzodiazepines or antidepressants

Keywords: myotonic dystrophy type 1 dm1 muscular dystrophy neuromuscular diseases
use of 18f-psma-11 pet for detection of lesions in iodine refractory thyroid cancers

Conditions: Thyroid Cancer

Summary: determine the diagnostic value of 18f-psma-11 in patients with iodine refractory thyroid cancer.


Eligibility criteria:
inclusion criteria: * patient is 18 years or older. * signed informed consent. * subject is diagnosed with a histologically confirmed differentiated thyroid carcinoma, that is considered rai refractory. there is evidence of persisting or recurrent disease, based on serum thyroglobulin levels and/or medical imaging. * subject should have a routine clinical 18f-fdg pet/ct performed within two months prior to the study scan. * female patients should be either post-menopausal, surgically sterile, or using highly effective contraceptives (methods that can achieve a failure rate of less than 1%: combined hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence). exclusion criteria: * patient has a known other active malignancy. * subject is potentially pregnant (urinary test can be performed in case of doubt) or breastfeeding. * patient is mentally or legally incapacitated.
nkg2d car-t cell therapy for patients with relapsed and/or refractory acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: a study of nkg2d car-t cell therapy for patients with relapsed and/or refractory acute myeloid leukemia.

this is a single arm, open-label, single-center study. this study is indicated for relapsed or refractory nkg2d ligand positive acute myeloid leukemia. the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 36 patients will be enrolled. primary objective is to explore the safety,main consideration is dose-related safety.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of nkg2d ligand positive aml per the us national comprehensive cancer network (nccn) clinical practice guidelines for acute myeloid leukemia (2016.v1); 2. relapsed or refractory nkg2d ligand positive aml (meeting one of the following conditions): 1. cr not achieved after standardized chemotherapy; 2. cr achieved following the first induction, but cr duration is less than 12 months; 3. ineffectively after first or multiple remedial treatments; 4. 2 or more relapses; 3. the number of primordial cells in bone marrow is \> 5% (by morphology), and/or \> 0.01% (by flow cyto metry); 4. total bilirubin ≤ 51 umol/l, alt and ast ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/l; 5. echocardiogram shows left ventricular ejection fraction (lvef) ≥50%; 6. no active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%; 7. estimated survival time ≥ 3 months; 8. ecog performance status 0 to 2; 9. patients or their legal guardians volunteer to participate in the study and sign the informed consent. exclusion criteria: subjects with any of the following exclusion criteria were not eligible for this trial: 1. history of craniocerebral trauma, conscious disturbance,epilepsy,cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases; 2. electrocardiogram shows prolonged qt interval, severe heart diseases such as severe arrhythmia in the past; 3. pregnant (or lactating) women; 4. patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis); 5. active infection of hepatitis b virus or hepatitis c virus; 6. concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving in haled steroids; 7. previously treated with any car-t cell product or other genetically modified t cell therapies; 8. creatinine\>2.5mg/dl, or alt / ast \> 3 times of normal amounts, or bilirubin\>2.0 mg/dl; 9. other uncontrolled diseases that were not suitable for this trial; 10. patients with hiv infection; 11. any situations that the investigator believes may increase the risk of patients or interfere with the results of study.

Keywords: acute myeloid leukemia car t-cell therapy nkg2d
hospital intensive monitoring of adverse drug reactions of qingkailing injection in the next two years

Conditions: Adverse Drug Events; Adverse Drug Reactions

Summary: to highlight the incidence of adverse reactions of qingkailing injection.


Eligibility criteria:
inclusion criteria: * all the patients treated by qingkailing injection in the certain centers(hospitals) in the next 2 years. * in accordance with ethics requirements. exclusion criteria: * none.
could medical educational video reduce anxiety before nasal packing removal after septoplasty/septorhinoplasty?

Conditions: Septum Deviated; Septoplasty/Septorhinoplasty

Summary: septoplasty/septorhinoplasty is one of the most common surgical procedures performed in ent clinics. intranasal packing is widely used post-operatively for nasal septum stabilization and bleeding control. patients experience pain after septoplasty during the removal of nasal packing. these patients may be concerned about pain before nasal packing removal, thus increasing anxiety levels. various methods are currently employed to reduce this pain. anxiety is a symptom when a person does not feel safe. anxiety levels can be objectively measured using different tests including spielberger state anxiety inventory. in this digital era, there is a growing tendency to use the popular internet sites as youtube, google as a new electronic learning for medical information. the quality of information found on youtube or other sources could be low and make people more anxious before a minor procedure. investigators aim to evaluate the effect of visual and auditory information prepared by the surgeon on anxiety level of patient at nasal packing removal after septoplasty/septorhinoplasty. for this purpose; patients who will undergo septo and septorhinoplasty at istanbul baskent university hospital are recruited. a video of nasal packing removal performed by the surgeon will be watched by the patient and spielberger state anxiety inventory will be filled out before nasal packing removal. the control group will fill out spielberger state anxiety inventory without watching the video before nasal packing removal. the scores of the groups will be compared and the effect of the video based information on anxiety will be revealed.


Eligibility criteria:
inclusion criteria: * patients who will undergo septoplasty/septorhinoplasty procedures * patients who will receive nasal packing at their septoplasty septorhinoplasty procedures exclusion criteria: * patients who will not want to participate to the study * revision surgeries * if the patient is taking antidepressants during the last 6 months * if the patient has a history of a disease that can affect anxiety levels * if patient wants to be excluded from the study

Keywords: septoplasty; nasal packing; anxiety; medical video
impact of fluid restriction policy in reducing the use of red cells in cardiac surgery

Conditions: Coronary Artery Disease; Coronary Artery Bypass; Erythrocyte Transfusion

Summary: the investigators' hypothesis is that restriction of circulating fluids in comparison to a liberal fluid administration policy would lead to a reduction of allogenic red blood cells exposure in patients undergoing cardiopulmonary bypass (cpb) for primary coronary artery bypass graft supported by reinfusion of washed shed blood from thoracic cavities.

192 patients operated under equal conditions were assigned prospectively and randomly either for a restrictive protocol for intravenous fluid administration (group a, 100 patients) or not (group b, 92 patients). transfusion guidelines were common for the two groups. the volumes of intravenous fluids, priming, "extra" volume on pump and cardioplegic solution and the volume of urine were recorded. net erythrocyte volume loss was calculated. the number of the transfused prc was analyzed as a continuous variable. "transfusion" was analyzed as a categorical characteristic. analysis employed student's two-tailed t-test, t-paired test and chitest.

Eligibility criteria:
inclusion criteria: * ejection fraction (ef) of left ventricle (lv) \> 35% * preoperative serum creatinine \< 150 μmol/l * preoperative haemoglobin \> 10/dl * peripheral anastomosis scheduled =\< 3 exclusion criteria: * redo bypass-emergency operations * prior coronal stenting * active congestive heart failure * documented myocardial infraction within the previous 6 weeks * nyha class \> 3 * carotid stenosis \> 50% * cva * inr \> 1.5 * chronic obstructive pulmonary disease (copd) * steroid therapy-chronic inflammatory process * use of aprotinin or tranexamic acid

Keywords: allogenic blood use total blood loss reinfusion of washed shed blood
association of periodontitis and preeclampsia during pregnancy

Conditions: Preeclampsia; Periodontal Disease

Summary: infections affecting the mother during pregnancy may produce alterations in the normal cytokine and hormone-regulated gestation, which could result in preeclampsia, preterm labor, premature rupture of membranes, and preterm birth. therefore, pregnant women with periodontal disease may show an alteration in the cytokine levels which may cause preeclampsia in them.

the enrolled subjects will be evaluated on the basis of a pre-designed and pre-tested proforma with respect to history and clinical examination, obstetrics examination and ultrasonography. the periodontal examination consists of assessments at vestibular, lingual, mesial and distal sites of all present teeth.five ml venous blood sample will be drawn from the patient at the time of enrollment before 20 weeks of gestation for the levels of cytokines (il-4, il-10, ifn-g and tnf-α. all the subjects will be followed- up till delivery. at the time of delivery, the details of pregnancy outcome (maternal and fetal) along with the measurement of the blood pressure will be recorded. a repeat of oral health evaluation will be done within 48 hours of delivery.

Eligibility criteria:
inclusion criteria: * singleton live pregnancy. * sure of her dates. (known dates of the last menstrual period) * age group 18-35 years. exclusion criteria: * chronic hypertension * polyhydramnios * congenital malformation in fetus * diabetes * renal disease * cardiovascular disease * urolithiasis * parathyroid disease * systolic blood pressure measurement of more than 140mm hg and diastolic blood pressure more than 90 mm hg at first visit. * infections (bacterial vaginosis and chorioamnionitis) * antibiotic use during pregnancy * excessive body mass index * less than 20 natural teeth

Keywords: preeclampsia periodontitis cytokines
long-term study of the safety of tanezumab in arthritis patients

Conditions: Osteoarthritis

Summary: tanezumab, administered for up to 1 1/2 years, reduces the pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves

this study was terminated on 11 nov 2010 following a us fda clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 june 2010 for potential safety issues.

Eligibility criteria:
inclusion criteria: * patients must consent in writing to participate in the study. * patients must be willing to comply with study visit schedule and study requirements, including, for women of child-bearing potential or male patients with female partners of child-bearing potential, the use of 2 forms of birth control, one of which is a barrier method. * patients must have participated in the a4091026 study. exclusion criteria: * withdrawn from the a4091026 study for an adverse event or serious adverse event. * pregnant women, lactating mothers, women suspected of being pregnant, and women who wish to be pregnant during the course of clinical study. * other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
comparison of safety and efficacy of de novo everolimus

Conditions: Cytomegalovirus Infections

Summary: nowadays, de novo everolimus regimen in renal transplant patients is considered for reduction of cyclosporine dose and it is mentioned that this regimen not only has similar safety and efficacy, but also could prevent cytomegalovirus (cmv )infections. so, the aim of this study was comparison of safety and efficacy of de novo everolimus plus low dose of cyclosporine with standard dose of cyclosporine plus cellcept on cmv virus infections prevention in renal transplant patients.

this randomized clinical trial was conducted in shahid labbafi nejad hospital. 35 renal transplanted patients enter the study and randomized to one of two groups: everolimus or control (sandimmun or tacrolimus). however, 34 patients completed study (17 patients in each group). the treatment regimen in everolimus group was 0.75 mg/bid everolimus with everolimus c0 3-8 ng/ml plus sandimmun (neoral) low dose and in control group was standard dose of sandimmun or tacrolimus plus cellcept. all patients gave antithymocyte glubolin and prednisolone. in addition, they gave cmv prophylaxis until 3 months. kidney biopsies were done for raise of creatinine or protocol biopsy at 6 month after transplantation. demographic, renal disease and transplantation characteristics, cmv and bk virus status, rejection, and routine laboratory tests recorded during study period and compared between two groups.

Eligibility criteria:
inclusion criteria: * adult transplanted patients \> 18 years exclusion criteria: * simultanous kidney -pancreas transplantation
the study of using esophageal pressure to guide the peep setting in abdominal hypertension patients who undergoing mechanical ventilation

Conditions: ARDS; Intra-abdominal Hypertension

Summary: intra-abdominal hypertension can increase the pleural pressure, and then end-expiratory transpulmonary pressures will be turn to negative, pulmonary atelectasis/acute lung injury/acute respiratory distress syndrome will appear. in the group of people who suffering intra-abdominal hypertension, the investigators use the pressure of esophagus to speculate the intrathoracic pressure, and to setting peep in order to decrease the happening of ali/ards, which may decrease morbidity in this population.


Eligibility criteria:
inclusion criteria: * intra-abdominal hypertension * mechanical ventilation * sedation exclusion criteria: * underlying pulmonary disease * age older than 60 years and younger than 18 years * vital signs were not stable * non voluntary

Keywords: mechanical ventilation intra-abdominal hypertension positive end-expiratory pressure
evaluation of glycemic control by flash monitoring of glucose (mfg) in malnourished patients with type 2 diabetes

Conditions: Diabetes Type 2; Malnutrition

Summary: evaluation of glycemic control by flash monitoring of glucose (mfg) in malnourished patients with type 2 diabetes (mfg sno)

in people with malnutrition and diabetes who require oral supplementation, there is no evidence clear when choosing a specific supplement for diabetes or a standard supplement. to date, there are no studies evaluating flash glucose monitoring in people with dm2 with supplements, nor studies comparing formulas specific for diabetes with standard formulas. patients with type 2 diabetes, malnutrition and requiring oral nutritional supplements for 3 months will be included in the study. a standard supplement (minimum 2 per day) will be prescribed for 2 weeks, an installation of the mfg system indicating that the scans are performed at start up, at the time and two hours after taking the oral supplement at home, as it doesn't happen anymore 8 hours without scanning to avoid losing information. after 14 days participants will go to consultation to download mfg data, assess acute response after taking of the supplement in the presence of health personnel (every 15 minutes for 4 hours). investigators will change the sensor and nutritional supplement to a specific diabetes formula, after 14 days participants will come for mfg data download and to assess acute response after taking the supplement in the presence of healthcare personnel. the results of the study will allow us to carry out a more appropriate treatment in this profile of patients, which is increasingly prevalent in our consultations.

Eligibility criteria:
inclusion criteria: * patients with dm2 under follow-up by the clinical nutrition and dietetics unit (uncyd) who present malnutrition or are at risk of malnutrition and require oral nutritional supplements, for a minimum estimated period of 3 months. exclusion criteria: * patients with dm1, steroid diabetes, pancreatic diabetes, dm2 treated with rapid insulin, glomerular filtration rate less than 30 ml/min/1.73m2, intolerance to the product, gastrectomy or gastroparesis. * patients who do not sign the consent informed.

Keywords: diabetes type 2 malnutrition mfg
balance after knee arthroplasty

Conditions: Postural Balance; Knee Arthroplasty; Quality of Life

Summary: evaluation of patients before and after knee arthroplasty regarding balance, function and quality of life. comparison of total and unicompartmental knee arthroplasty. comparison of the primary outcome parameter and selected secondary outcome parameters to healthy controls.


Eligibility criteria:
inclusion criteria: * primary gonarthrosis * planned tka or uka * adequate cognitive and lingual competence * informed consent exclusion criteria: * tka or uka revision * surgery after trauma * rheumatic disease * neurologic disease * previous arthroplasty of the lower extremity (\<9 months) * cardiovascular disease * restricted weight bearing of the lower extremity after surgery